Lv21
112 积分 2021-12-03 加入
Can PROTACs truly become oral drugs?
1个月前
已完结
Clinical Translation of Targeted Protein Degraders
2个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
2个月前
已完结
Regulatory Considerations for Heterobifunctional Degraders and Proximity Inducers
2个月前
已完结
ToxicitiesofPARPinhibitorsingenitourinarycancers
4个月前
已关闭
Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis
4个月前
已完结
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer
5个月前
已完结
MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies
7个月前
已关闭
Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients
7个月前
已关闭
Fundamental aspects of DMPK optimization of targeted protein degraders
9个月前
已完结
皖公网安备34019202002308
